Heartsciences announces completion of patient enrollment for fda pivotal study of myovista wavecg

Southlake, texas, may 09, 2023 (globe newswire) -- heart test laboratories, inc. d/b/a heartsciences (nasdaq: hscs; hscsw) (“heartsciences” or the “company”), an artificial intelligence (ai)-based medical technology company focused on transforming ecgs/ekgs to save lives through the early detection of heart disease, today announces completion of patient enrollment for its myovista wavecg pivotal study for fda de novo submission.
HSCS Ratings Summary
HSCS Quant Ranking